Tidetron Completes Series A+ Financing with Legend Capital Re-upped

Tidetron Bioworks, a rising star in achieving mass-producing multiple synthetic biology, recently announced its completion of Series A+ financing. The new round is the fourth investment to this one-year-old startup which brought its total fundraising size to over USD100 million. As the lead investor of Tidetron’s Series A financing, Legend Capital continued to support its development by joining this financing round.

Synthetic biology, a frontier science that has developed rapidly in recent years, is deemed "the 3rd biotech revolution". Its vast commercial potential makes itself sought after by global investment institutions. According to CB Insights, the global market size of synthetic biology reached USD5.3 billion in 2019 and is expected to grow to USD18.9 billion in 2024.

Legend Capital has long paid great attention to synthetic biology and bio-based material, both are combinations of information science, life science and material science. In addition, Legend Capital targets to build an ecosystem focused on the industrial chain, and seeks the suitable opportunity to invest along industrial development and technological evolution.

Legend Capital has been focusing on energy decarbonization, terminal electrification and intelligentization, and synthetic biology, making successful investments in many outstanding startups such as GS Biotech and Tidetron Bioworks.

Tidetron was founded in 2021 by Zhiqian ZHANG, a doctoral student in clinical medicine at the Zhongshan School of Medicine at Sun Yat-sen University. Zhang has devoted himself to researching synthetic biology since 2016. With the accumulation of experience and technology, Tidetron leveraged technologies including multiple gene-editing tools, directed evolution, and microfluidics to build its platform Tidetron Altra, which enabled the mass production of biologically fermented raw materials for industries like skincare, food additives, biopharmaceuticals, and green agriculture.

With indefatigable practice and its spirit of seeking technical breakthrough, within a year since Tidetron's establishment, the factory’s annual production capacity has exceeded 10,000 tons and the company realized profits quickly by transferring higher-quality raw material for well-known enterprises successfully. According to reports, very few synthetic biology enterprises in China achieved mass production. Tidetron has attracted much attention in the industry as it has been recognized as one of the first synthetic biology enterprises in China to realize mass production of multiple synthetic products.